662 related articles for article (PubMed ID: 30171992)
1. Cannabidiol as a suggested candidate for treatment of autism spectrum disorder.
Poleg S; Golubchik P; Offen D; Weizman A
Prog Neuropsychopharmacol Biol Psychiatry; 2019 Mar; 89():90-96. PubMed ID: 30171992
[TBL] [Abstract][Full Text] [Related]
2. Cannabinoid treatment for the symptoms of autism spectrum disorder.
Aran A; Cayam Rand D
Expert Opin Emerg Drugs; 2024 Mar; 29(1):65-79. PubMed ID: 38226593
[TBL] [Abstract][Full Text] [Related]
3. Cannabidiol for the treatment of autism spectrum disorder: hope or hype?
Pedrazzi JFC; Ferreira FR; Silva-Amaral D; Lima DA; Hallak JEC; Zuardi AW; Del-Bel EA; Guimarães FS; Costa KCM; Campos AC; Crippa ACS; Crippa JAS
Psychopharmacology (Berl); 2022 Sep; 239(9):2713-2734. PubMed ID: 35904579
[TBL] [Abstract][Full Text] [Related]
4. Brief Report: Cannabidiol-Rich Cannabis in Children with Autism Spectrum Disorder and Severe Behavioral Problems-A Retrospective Feasibility Study.
Aran A; Cassuto H; Lubotzky A; Wattad N; Hazan E
J Autism Dev Disord; 2019 Mar; 49(3):1284-1288. PubMed ID: 30382443
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder: randomized, double-blind, and placebo-controlled clinical trial.
Silva EAD; Medeiros WMB; Santos JPMD; Sousa JMM; Costa FBD; Pontes KM; Borges TC; Espínola C; Andrade E Silva AH; Nunes ELG; Alves NT; Rosa MDD; Albuquerque KLGD
Trends Psychiatry Psychother; 2024; 46():e20210396. PubMed ID: 35617670
[TBL] [Abstract][Full Text] [Related]
6. Autism Spectrum Disorder: Classification, diagnosis and therapy.
Sharma SR; Gonda X; Tarazi FI
Pharmacol Ther; 2018 Oct; 190():91-104. PubMed ID: 29763648
[TBL] [Abstract][Full Text] [Related]
7. The effect of cannabidiol (CBD) on low-frequency activity and functional connectivity in the brain of adults with and without autism spectrum disorder (ASD).
Pretzsch CM; Voinescu B; Mendez MA; Wichers R; Ajram L; Ivin G; Heasman M; Williams S; Murphy DG; Daly E; McAlonan GM
J Psychopharmacol; 2019 Sep; 33(9):1141-1148. PubMed ID: 31237191
[TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of Medical Cannabis in Autism Spectrum Disorder Compared with Commonly Used Medications.
Holdman R; Vigil D; Robinson K; Shah P; Contreras AE
Cannabis Cannabinoid Res; 2022 Aug; 7(4):451-463. PubMed ID: 34432543
[No Abstract] [Full Text] [Related]
9. Behavioral aspects and neurobiological properties underlying medical cannabis treatment in Shank3 mouse model of autism spectrum disorder.
Poleg S; Kourieh E; Ruban A; Shapira G; Shomron N; Barak B; Offen D
Transl Psychiatry; 2021 Oct; 11(1):524. PubMed ID: 34645786
[TBL] [Abstract][Full Text] [Related]
10. Targets for Drug Therapy for Autism Spectrum Disorder: Challenges and Future Directions.
Lacivita E; Perrone R; Margari L; Leopoldo M
J Med Chem; 2017 Nov; 60(22):9114-9141. PubMed ID: 29039668
[TBL] [Abstract][Full Text] [Related]
11. Implications of the endocannabinoid system and the therapeutic action of cannabinoids in autism spectrum disorder: A literature review.
de Camargo RW; de Novais Júnior LR; da Silva LM; Meneguzzo V; Daros GC; da Silva MG; de Bitencourt RM
Pharmacol Biochem Behav; 2022 Nov; 221():173492. PubMed ID: 36379443
[TBL] [Abstract][Full Text] [Related]
12. Cannabis and cannabinoid use in autism spectrum disorder: a systematic review.
Silva EAD; Medeiros WMB; Torro N; Sousa JMM; Almeida IBCM; Costa FBD; Pontes KM; Nunes ELG; Rosa MDD; Albuquerque KLGD
Trends Psychiatry Psychother; 2022 Jun; 44():e20200149. PubMed ID: 34043900
[TBL] [Abstract][Full Text] [Related]
13. Autism Spectrum Disorder and Medical Cannabis: Review and Clinical Experience.
Mostafavi M; Gaitanis J
Semin Pediatr Neurol; 2020 Oct; 35():100833. PubMed ID: 32892960
[TBL] [Abstract][Full Text] [Related]
14. Psychopharmacological interventions in autism spectrum disorder.
Accordino RE; Kidd C; Politte LC; Henry CA; McDougle CJ
Expert Opin Pharmacother; 2016; 17(7):937-52. PubMed ID: 26891879
[TBL] [Abstract][Full Text] [Related]
15. A pediatric patient with autism spectrum disorder and epilepsy using cannabinoid extracts as complementary therapy: a case report.
Ponton JA; Smyth K; Soumbasis E; Llanos SA; Lewis M; Meerholz WA; Tanguay RL
J Med Case Rep; 2020 Sep; 14(1):162. PubMed ID: 32958062
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological management of behavioral disturbances in children and adolescents with autism spectrum disorders.
Lamy M; Erickson CA
Curr Probl Pediatr Adolesc Health Care; 2018 Oct; 48(10):250-264. PubMed ID: 30262163
[TBL] [Abstract][Full Text] [Related]
17. Cannabidiol is a behavioral modulator in BTBR mouse model of idiopathic autism.
Shrader SH; Mellen N; Cai J; Barnes GN; Song ZH
Front Neurosci; 2024; 18():1359810. PubMed ID: 38784096
[TBL] [Abstract][Full Text] [Related]
18. Use of psychotropic drugs in patients with autism spectrum disorders: a systematic review.
Jobski K; Höfer J; Hoffmann F; Bachmann C
Acta Psychiatr Scand; 2017 Jan; 135(1):8-28. PubMed ID: 27624381
[TBL] [Abstract][Full Text] [Related]
19. A Single Dose, Randomized, Controlled Proof-Of-Mechanism Study of a Novel Vasopressin 1a Receptor Antagonist (RG7713) in High-Functioning Adults with Autism Spectrum Disorder.
Umbricht D; Del Valle Rubido M; Hollander E; McCracken JT; Shic F; Scahill L; Noeldeke J; Boak L; Khwaja O; Squassante L; Grundschober C; Kletzl H; Fontoura P
Neuropsychopharmacology; 2017 Aug; 42(9):1914-1923. PubMed ID: 27711048
[TBL] [Abstract][Full Text] [Related]
20. Effects of CBD-Enriched
Fleury-Teixeira P; Caixeta FV; Ramires da Silva LC; Brasil-Neto JP; Malcher-Lopes R
Front Neurol; 2019; 10():1145. PubMed ID: 31736860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]